Last reviewed · How we verify

NCT04046497

Artificial Intelligence to Measure Adherence to Oral Medication

Recruiting now Phase 4 Last updated 19 September 2024
What this trial tests

Phase 4 trial testing Smartphone App in First Episode Psychosis in 200 participants. Currently enrolling.

Timeline
20 November 2020
Primary endpoint
30 November 2024
31 December 2024

Quick facts

Lead sponsorNorthwell Health
PhasePhase 4
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment200
Start date20 November 2020
Primary completion30 November 2024
Estimated completion31 December 2024
Sites5 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Northwell Health — full company profile →

Who can join

Adults 15 to 40, any sex, with First Episode Psychosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Smartphone App

Trials testing the same drug.

Other recruiting trials for First Episode Psychosis

Currently open trials in the same condition.

Other Northwell Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04046497.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing